The down-regulation of hTRM9L was more pronounced in stage IV cancer, suggesting a progressive loss of hTRM9L expression coincided with the acquisition of a more aggressive phenotype and perhaps a later event in progression. The gene discussed is TRMT9B; the disease is cancer.